MedStar Authors catalog › Details for: Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.
Normal view MARC view ISBD view

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

by Fishbein, Dawn.
Citation: New England Journal of Medicine. 373(8):714-25, 2015 Aug 20..Journal: The New England journal of medicine.ISSN: 0028-4793.Full author list: Wyles DL; Ruane PJ; Sulkowski MS; Dieterich D; Luetkemeyer A; Morgan TR; Sherman KE; Dretler R; Fishbein D; Gathe JC Jr; Henn S; Hinestrosa F; Huynh C; McDonald C; Mills A; Overton ET; Ramgopal M; Rashbaum B; Ray G; Scarsella A; Yozviak J; McPhee F; Liu Z; Hughes E; Yin PD; Noviello S; Ackerman P; ALLY-2 Investigators.UI/PMID: 26196502.Subject(s): Adult | Aged | Anti-Retroviral Agents/tu [Therapeutic Use] | Antiviral Agents/ae [Adverse Effects] | *Antiviral Agents/tu [Therapeutic Use] | Drug Resistance, Viral | Drug Therapy, Combination | Female | Genotype | *HIV Infections/co [Complications] | HIV Infections/dt [Drug Therapy] | *HIV-1 | Hepacivirus/de [Drug Effects] | Hepacivirus/ge [Genetics] | Hepacivirus/ip [Isolation & Purification] | *Hepacivirus | Hepatitis C, Chronic/co [Complications] | *Hepatitis C, Chronic/dt [Drug Therapy] | Humans | Imidazoles/ae [Adverse Effects] | *Imidazoles/tu [Therapeutic Use] | Male | Middle Aged | RNA, Viral/bl [Blood] | Uridine Monophosphate/ae [Adverse Effects] | *Uridine Monophosphate/aa [Analogs & Derivatives] | Uridine Monophosphate/tu [Therapeutic Use] | Viral LoadInstitution(s): MedStar Washington Hospital CenterDepartment(s): Medicine/Infectious DiseasesActivity type: Journal Article.Medline article type(s): Journal Article | Multicenter Study | Randomized Controlled Trial | Research Support, Non-U.S. Gov'tOnline resources: Click here to access online Digital Object Identifier: (Click here) Abbreviated citation: N Engl J Med. 373(8):714-25, 2015 Aug 20.Local Holdings: Available online from MWHC library: 1993 - present, Available in print through MWHC library: 1980 - present.Abstract: BACKGROUND: The combination of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and the NS5B inhibitor sofosbuvir has shown efficacy in patients with HCV monoinfection. Data are lacking on the efficacy and safety of this combination in patients coinfected with human immunodeficiency virus type 1 (HIV-1).Abstract: METHODS: This was an open-label study involving 151 patients who had not received HCV treatment and 52 previously treated patients, all of whom were coinfected with HIV-1. Previously untreated patients were randomly assigned in a 2:1 ratio to receive either 12 weeks or 8 weeks of daclatasvir at a standard dose of 60 mg daily (with dose adjustment for concomitant antiretroviral medications) plus 400 mg of sofosbuvir daily. Previously treated patients were assigned to undergo 12 weeks of therapy at the same doses. The primary end point was a sustained virologic response at week 12 after the end of therapy among previously untreated patients with HCV genotype 1 who were treated for 12 weeks.Abstract: RESULTS: Patients had HCV genotypes 1 through 4 (83% with genotype 1), and 14% had compensated cirrhosis; 98% were receiving antiretroviral therapy. Among patients with genotype 1, a sustained virologic response was reported in 96.4% (95% confidence interval [CI], 89.8 to 99.2) who were treated for 12 weeks and in 75.6% (95% CI, 59.7 to 87.6) who were treated for 8 weeks among previously untreated patients and in 97.7% (95% CI, 88.0 to 99.9) who were treated for 12 weeks among previously treated patients. Rates of sustained virologic response across all genotypes were 97.0% (95% CI, 91.6 to 99.4), 76.0% (95% CI, 61.8 to 86.9), and 98.1% (95% CI, 89.7 to 100), respectively. The most common adverse events were fatigue, nausea, and headache. There were no study-drug discontinuations because of adverse events. HIV-1 suppression was not compromised.Abstract: CONCLUSIONS: Among previously untreated HIV-HCV coinfected patients receiving daclatasvir plus sofosbuvir for HCV infection, the rate of sustained virologic response across all genotypes was 97.0% after 12 weeks of treatment and 76.0% after 8 weeks. (Funded by Bristol-Myers Squibb; ALLY-2 number, NCT02032888.).

Powered by Koha